BenzingaAugust 10, 2026 at 6:13 AM NY25 days ago
Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14
Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
Which dow jones stocks are moving on Friday?
ChartMill1 hour ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill1 hour ago
Sector Update: Financial
Yahoo3 hours ago
Should You Buy, Sell or Hold PVH Stock Post Q2 Earnings?
Yahoo3 hours ago
Will Fiserv’s (FISV) Cut 2026 Outlook and Margin Pressures Change Its Transformation Narrative?
Yahoo3 hours ago